102 related articles for article (PubMed ID: 24968817)
1. Downregulation of HNF1 homeobox B is associated with drug resistance in ovarian cancer.
Li J; Zhang Y; Gao Y; Cui Y; Liu H; Li M; Tian Y
Oncol Rep; 2014 Sep; 32(3):979-88. PubMed ID: 24968817
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of NEK11 is associated with drug resistance in ovarian cancer.
Liu X; Gao Y; Lu Y; Zhang J; Li L; Yin F
Int J Oncol; 2014 Sep; 45(3):1266-74. PubMed ID: 24969318
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of tumor suppressor gene ribonuclease T2 and gametogenetin binding protein 2 is associated with drug resistance in ovarian cancer.
Yin F; Liu L; Liu X; Li G; Zheng L; Li D; Wang Q; Zhang W; Li L
Oncol Rep; 2014 Jul; 32(1):362-72. PubMed ID: 24842157
[TBL] [Abstract][Full Text] [Related]
4. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
Zou J; Yin F; Wang Q; Zhang W; Li L
Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer.
Liu X; Zou J; Su J; Lu Y; Zhang J; Li L; Yin F
Int J Oncol; 2016 Jan; 48(1):243-52. PubMed ID: 26647723
[TBL] [Abstract][Full Text] [Related]
6. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
8. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
Fang L; Wang H; Li P
Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of NEK2 is associated with drug resistance in ovarian cancer.
Liu X; Gao Y; Lu Y; Zhang J; Li L; Yin F
Oncol Rep; 2014 Feb; 31(2):745-54. PubMed ID: 24337664
[TBL] [Abstract][Full Text] [Related]
10. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiles in three histologic types, clear-cell, endometrioid and serous ovarian carcinomas.
Pamuła-Piłat J; Rubel T; Rzepecka IK; Olbryt M; Herok R; Dansonka-Mieszkowska A; Grzybowska E; Kupryjańczyk J
J Biol Regul Homeost Agents; 2014; 28(4):659-74. PubMed ID: 25620176
[TBL] [Abstract][Full Text] [Related]
12. [Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues].
Zhang Q; He XJ; Ma LP; Li N; Yang J; Cheng YX; Cui H
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):885-90. PubMed ID: 22340095
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatic analysis of chemokine (C-C motif) ligand 21 and SPARC-like protein 1 revealing their associations with drug resistance in ovarian cancer.
Yin F; Liu X; Li D; Wang Q; Zhang W; Li L
Int J Oncol; 2013 Apr; 42(4):1305-16. PubMed ID: 23404140
[TBL] [Abstract][Full Text] [Related]
14. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
15. Integrative bioinformatics links HNF1B with clear cell carcinoma and tumor-associated thrombosis.
Cuff J; Salari K; Clarke N; Esheba GE; Forster AD; Huang S; West RB; Higgins JP; Longacre TA; Pollack JR
PLoS One; 2013; 8(9):e74562. PubMed ID: 24040285
[TBL] [Abstract][Full Text] [Related]
16. Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells.
Li J; Wood WH; Becker KG; Weeraratna AT; Morin PJ
Oncogene; 2007 May; 26(20):2860-72. PubMed ID: 17072341
[TBL] [Abstract][Full Text] [Related]
17. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray.
Sakamoto M; Kondo A; Kawasaki K; Goto T; Sakamoto H; Miyake K; Koyamatsu Y; Akiya T; Iwabuchi H; Muroya T; Ochiai K; Tanaka T; Kikuchi Y; Tenjin Y
Hum Cell; 2001 Dec; 14(4):305-15. PubMed ID: 11925933
[TBL] [Abstract][Full Text] [Related]
18. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
[TBL] [Abstract][Full Text] [Related]
19. [Gene expression profiling of human ovarian epithelial tumors by digo nucleotide microarray].
Konno R
Hum Cell; 2001 Dec; 14(4):261-6. PubMed ID: 11925926
[TBL] [Abstract][Full Text] [Related]
20. Discovery of microarray-identified genes associated with ovarian cancer progression.
Liu X; Gao Y; Zhao B; Li X; Lu Y; Zhang J; Li D; Li L; Yin F
Int J Oncol; 2015; 46(6):2467-78. PubMed ID: 25891226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
